PMID- 11227730
OWN - NLM
STAT- MEDLINE
DCOM- 20010524
LR  - 20181113
IS  - 0391-4097 (Print)
IS  - 0391-4097 (Linking)
VI  - 24
IP  - 1
DP  - 2001 Jan
TI  - Administration of glutathione in patients with type 2 diabetes mellitus increases 
      the platelet constitutive nitric oxide synthase activity and reduces PAI-1.
PG  - 37-41
AB  - Several studies suggest that nitric oxide (NO) production is impaired in diabetes 
      mellitus. Reduced levels of NO could contribute to cardiovascular mortality. 
      Furthermore, NO synthesis is impaired in glutathione (GSH)-depleted human 
      umbilical vein endothelial cells and GSH is reduced in patients with type 2 
      diabetes mellitus (T2DM). We tested the hypothesis that treatment with GSH may 
      improve platelet constitutive NO sinthase (cNOS) activity in patients with T2DM. 
      Fifteen patients with T2DM underwent a treatment with GSH 600 mg/day i.m. for 10 
      days. With respect to the basal values on the 10th day of treatment, the red 
      blood cell GSH concentration and platelets cNOS increased (1.4+/-0.1 vs 1.9+/-0.1 
      micromol/10(10) RBC, p<0.001 and 0.7+/-0.1 vs 2.9+/-0.2 fmol x min(-1) x 10(-9) 
      PLTs, p<0.001, respectively) and the plasma PAI-1 levels diminished (81.4+/-3.7 
      vs 68.7+/-4.0 ng/ml, p<0.002). A negative correlation between the cNOS and the 
      PAI-1 was found on the basal values. After a wash-out of 30 days the values of 
      red blood cell GSH concentration, platelet cNOS activity and PAI-1 Ag returned to 
      the basal levels. These data suggest that the administration of GSH, in patients 
      with T2DM, is able to improve platelet cNOS activity together with a reduction of 
      PAI-1.
FAU - Martina, V
AU  - Martina V
AD  - Department of Internal Medicine, University of Torino, Italy. camanni@pianeta.net
FAU - Bruno, G A
AU  - Bruno GA
FAU - Zumpano, E
AU  - Zumpano E
FAU - Origlia, C
AU  - Origlia C
FAU - Quaranta, L
AU  - Quaranta L
FAU - Pescarmona, G P
AU  - Pescarmona GP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (NOS3 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - GAN16C9B8O (Glutathione)
SB  - IM
MH  - Aged
MH  - Blood Platelets/*enzymology
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Endothelium, Vascular/metabolism
MH  - Erythrocytes/metabolism
MH  - Female
MH  - Glutathione/administration & dosage/blood/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide/biosynthesis
MH  - Nitric Oxide Synthase/*blood
MH  - Nitric Oxide Synthase Type III
MH  - Plasminogen Activator Inhibitor 1/*blood
MH  - Umbilical Veins
EDAT- 2001/03/03 10:00
MHDA- 2001/05/26 10:01
CRDT- 2001/03/03 10:00
PHST- 2001/03/03 10:00 [pubmed]
PHST- 2001/05/26 10:01 [medline]
PHST- 2001/03/03 10:00 [entrez]
AID - 10.1007/BF03343806 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2001 Jan;24(1):37-41. doi: 10.1007/BF03343806.